Life Code GmbH

Highlights

ASCO 2026 Highlights | Robert F. Siegmund, PhD MBA has just wrapped up. I pulled together the 10 cancer trial results that stood out this year. Read the article in my newsletter "Biopharma Insights & AI" 👇

HELLO from Future Labs Live Basel

If you are working on digital labs, R&D data workflows, discovery analytics, translational research, biomarkers, omics, cheminformatics, or AI-ready research infrastructure, I would be very happy to meet you.

helps biopharma R&D teams bring visual clarity into complex biomedical and chemical datasets — integrating public and proprietary data into interactive, traceable workflows. The platform ecosystem includes Ordino, Aevidence and visynKB, with curated access to 80+ biomedical data sources.

Please feel free to reach out here on LinkedIn or come and say hello at the conference when you see me!

At Live still 2 hours if you want to talk to me about visual data science for drug discovery 💡

Photo with Dr. Kevin Keim, Dr. Andrea Bocchio and Dr. Matthias Gross (from right to left).

For those that I didnt see I am also at the meeting in Markthalle Basel tonight and of course you can always reach out via Email or via X direct message.

Meet me at the Future Labs Conference in Basel

#futurelabs #futurelabslive #basel #datavisyn #drugdiscovery #biopharma #datascience #visualanalytics | Robert F. Siegmund, PhD MBA I am LIVE tomorrow and on Thursday, representing datavisyn. If you are working on digital labs, R&D data workflows, discovery analytics, translational research, biomarkers, omics, cheminformatics, or AI-ready research infrastructure, I would be very happy to connect. datavisyn helps biop...

Swiss Biotech Day 2026: clinical-stage company snapshots

Swiss Biotech Day 2026: clinical-stage company snapshots Following Swiss Biotech Day 2026 in Basel, I wanted to share a more structured follow-up on one of the most interesting parts of the event: the clinical-stage biotech company presentations. Across the two days, these presentations offered a useful view of where biotech innovation is heading: more sp

I will be at the SWISS BIOTECH DAY 2026 representing Life Code (biopharma forecasting), Psyma+Exevia (biopharma insights) and datavisyn (visual data science enabling biopharma discovery).

Lots to talk about - meet me at the Congress Center in Basel on the 4th and 5th May.

AI Live by our partner firm PSYMA+EXEVIA
Depth and Speed in

I am pleased to announce a new collaboration with DATAVISYN, a leading visual data science company based in my hometown of Linz, Austria, focused on enabling discovery in biopharmaceutical R&D.

In many R&D organizations, critical decisions are still slowed down by fragmented data, disconnected evidence sources, and workflows that are difficult to reproduce or explain.

datavisyn addresses this challenge with a suite of interactive platforms—Ordino and Aevidence—that bring together complex biological and chemical data and curated scientific evidence into a single, intuitive workflow. This enables research teams to explore, prioritize, and validate targets in a more integrated, transparent, and ultimately faster way. Backbone of our products is a unique curated database of public data from 80+ biological, compound, drug, and disease-specific repositories.

What I find particularly compelling is the emphasis on traceability and usability: analyses can be reproduced, shared, and revisited, moving beyond fragmented workflows and disconnected tools, and towards decisions that are both data-driven and explainable.

In my role as Business Development Partner at datavisyn, I bring a combination of scientific, strategic, and analytical experience, from a PhD in molecular biology and early R&D work to many years in insights and strategy in pharma, complemented by a strong focus on data science, analytics, and data visualization. I have always seen data visualization as both an art and a science—critical for turning complexity into clarity.

My focus will be on supporting biopharma and biotech companies in Switzerland, leveraging my network across R&D to connect datavisyn’s capabilities to concrete, high-impact use cases in discovery and translational research.

If you are currently working through challenges around target prioritization, evidence integration, or decision traceability in R&D, I would be glad to connect and arrange a short discussion or demonstration.